Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugsRead more
Cannabis Act; phased implementation of the Act and its impact on medical patients; development of regulations for the industry and the resulting tax implications of these regulations.
Varun Srivatsan · Director of Policy, Finance Canada (FIN)
Cannabis Act; phased implementation of the Act and its impact on medical patients; development of regulations for the industry and the resulting tax implications of these regulations.Read more
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
Michael Hamm · Director of Policy, Veterans Affairs Canada (VAC)
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
David Pellmann · Director General, Health Canada (HC)
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugsRead more
Regulations affiliated with Bill C- 45 regarding the legalization of cannabis. Formerly known as Bill C-45: An Act Respecting Cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts.
Canada's policy regarding the rules governing the legalization of marijuana
Regulations affiliated with Bill C- 45 regarding the legalization of cannabis. Formerly known as Bill C-45: An Act Respecting Cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts.Read more
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
Cathay Wagantall · Member of Parliament, House of Commons
Cannabis Act; phased implementation of the Act and its impact on medical patients; development of regulations for the industry and the resulting tax implications of these regulations.Read more
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
Cannabis Act; phased implementation of the Act and its impact on medical patients; development of regulations for the industry and the resulting tax implications of these regulations.Read more
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
Bryn Savage · Senior Policy Advisor, Health Canada (HC)
Cannabis Act; phased implementation of the Act and its impact on medical patients; development of regulations for the industry and the resulting tax implications of these regulations.Read more
Governmental policy towards medical cannabis research, product quality standards, medical cost coverage, and displacement of harder and more addictive drugs
Brandan Rowe · Chief of Staff, Intergovernmental Affairs Secretariat (IGA)
Sandenga Yeba · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
Advocate for the removal of unnecessary barriers to health product regulations and encourage the development of a detailed plan to implement a modernized National Self Care FrameworkRead more
Engage officials on international and cross-border trade issues
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.